Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New analysis shows the lower range of the licensed dose of the most commonly used second-generation antidepressants achieves the optimal balance between efficacy, tolerability and acceptability in the acute treatment of adults with major depression.

A new study from Department of Psychiatry, Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis, was published in The Lancet Psychiatry.It demonstrates important clinical implications for guidelines and the daily use of antidepressants in real world settings.

The study focused on the most frequently prescribed antidepressants in the UK, including five SSRIs (selective serotonin reuptake inhibitors: citalopram, escitalopram, fluoxetine, paroxetine and sertraline), venlafaxine and mirtazapine. Data from 19,364 participants was used to assess efficacy, acceptability and tolerability over a median of 8 weeks treatment.

Read more (Department of Psychiatry website)

Similar stories

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.

Opportunities for final goodbyes must be prioritised in COVID-19 pandemic

Coronavirus COVID-19 General Research

Bereaved relatives described the ongoing pain of being absent at the end of a loved-one's life. Many had not seen their relative for weeks or months due to the pandemic. Opportunities must be prioritised for essential connections between families at end-of-life care.

New study shows overwhelming public support for donating vaccines to low-income countries

Coronavirus COVID-19 General Research

A survey led by Nuffield Department of Population Health's Health Economics Research Centre has found that most people in high-income countries support donating some of their country’s COVID-19 vaccine supplies to low-income nations who would otherwise struggle to gain access.